<SEC-DOCUMENT>0001193125-23-062570.txt : 20230307
<SEC-HEADER>0001193125-23-062570.hdr.sgml : 20230307
<ACCEPTANCE-DATETIME>20230307102627
ACCESSION NUMBER:		0001193125-23-062570
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230307
FILED AS OF DATE:		20230307
DATE AS OF CHANGE:		20230307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		23711440

	BUSINESS ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d325782d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Private Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>under the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March&nbsp;7, 2023 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35203</FONT> </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 Peel
Street, Suite 1100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montr&eacute;al, Qu&eacute;bec, Canada </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H3A 1T8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of
principal executive offices) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9746;</FONT> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1): </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check
mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7): </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule <FONT STYLE="white-space:nowrap">12g3-2(b)</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule
<FONT STYLE="white-space:nowrap">12g3-2(b):</FONT> <FONT STYLE="white-space:nowrap">82-</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THERATECHNOLOGIES INC.</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release Dated March&nbsp;7, 2023</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THERATECHNOLOGIES INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>/s/ Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;7, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d325782dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g325782g0307200559706.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MONTREAL, March&nbsp;7, 2023 (GLOBE NEWSWIRE) &#151; Theratechnologies Inc. (&#147;Theratechnologies&#148; or the &#147;Company&#148;) (TSX: TH) (NASDAQ:
THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the &#147;Notification Letter&#148;) from The Nasdaq Stock Market LLC (&#147;Nasdaq&#148;)
dated March&nbsp;3, 2023, advising that the Company was not in compliance with Listing Rule 5550(a)(2) as the bid price of the Company&#146;s listed securities had closed at less than US$1.00 per share over the last 30 consecutive business days (the
&#147;Minimum Bid Price Requirement&#148;) from January&nbsp;19, 2023 to March&nbsp;2, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A),
the Company has a period of 180 calendar days from the date of the Notification Letter, until August&nbsp;30, 2023 (the &#147;Compliance Period&#148;), to regain compliance with the Minimum Bid Price Requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If at any time before the expiration of the Compliance Period the bid price of the Company&#146;s common shares (the &#147;Shares&#148;) closes at or above
US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nasdaq Notification Letter does not affect <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> trading and does not
result in the delisting of the Company&#146;s Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Theratechnologies Shares are also listed on the Toronto Stock Exchange, and the Nasdaq Notification
Letter does not affect the Company&#146;s compliance status with that listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company does not regain compliance by the end of the Compliance
Period, the Company may be eligible for an additional 180 calendar day period to regain compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To qualify for that additional 180 calendar day
period, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will
need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency,
or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company&#146;s securities will be subject to delisting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
intends to continue actively monitoring the bid price for its Shares between now and the expiration of the Compliance Period and will consider all available options to resolve the deficiency with every intention to regain compliance with the Minimum
Bid Price Requirement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Theratechnologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing
unmet medical needs. Further information about Theratechnologies is available on the Company&#146;s website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements and forward-looking information (collectively, &#147;Forward-Looking Statements&#148;), within the
meaning of applicable securities laws, that are based on our management&#146;s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as &#147;may&#148;,
&#147;will&#148;, &#147;should&#148;, &#147;could&#148;, &#147;would&#148;, &#147;outlook&#148;, &#147;believe&#148;, &#147;plan&#148;, &#147;envisage&#148;, &#147;anticipate&#148;, &#147;expect&#148; and &#147;estimate&#148;, or the negatives of
these terms, or variations of them. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the Compliance Period and, failing such compliance, that it will meet the continued listing
requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, to benefit from the additional 180 calendar day period to regain compliance
with Nasdaq rules. We refer current and potential investors to the &#147;Risk Factors&#148; section of our Annual Information Form dated February&nbsp;27, 2023 available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our
report on Form <FONT STYLE="white-space:nowrap">40-F</FONT> dated February&nbsp;28, 2023 under Theratechnologies&#146; public filings for additional risks related to the Company. The reader is cautioned to consider these and other risks and
uncertainties carefully and not to put undue reliance on Forward-Looking Statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations
as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor inquiries: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elif McDonald </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@theratech.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-438-315-8563</FONT></FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g325782g0307200559706.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g325782g0307200559706.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ *0# 2(  A$! Q$!_\0
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M]#D=0?Z5PWCV=_$WCW2O#4#9BA<&;'9FY;\E'ZU#HQ'@KXLW&F?<L;\A(QV
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
